2016 Webinar: New Concepts and Insights Into HBV Immunology
Recorded On: 10/11/2016
This webinar will review the current state of the understanding of the immune response to hepatitis b (HBV). Two experts and one moderator will guide providers through an understanding of the HBV immune interactions that can help providers understand and help explain HBV infections, guide patient management and help embrace new therapies.
Robert G. Gish (Moderator)
Dr. Robert G. Gish is a Clinical Professor of Medicine at the University of Nevada in Las Vegas and is a senior consultant at St Joseph’s Medical Center in Phoenix as well as Professor Consultant, Stanford University. In 2013, he founded the consulting company Robert G. Gish Consultants, LLC to provide consultative support to Pharma, nonprofits and hepatology centers and liver transplant programs that wish to start or grow their programs through pathways of quality and optimal patient care that is integrated with research and education. Dr. Gish began his medical training in 1974 when he was enrolled in the pharmacy school at the University of Kansas and then transferred to the University of Kansas Medical School in 1977 and finished his Doctor of Medicine degree in 1980. Dr. Gish went on to complete a three year internal medicine residency at the University of California, San Diego and a four-year gastroenterology and hepatology fellowship at the University of California, Los Angeles. Dr. Gish has had and continues to have an active research program in viral hepatitis, liver transplant, bio-artificial liver, and public policy especially related to liver cancer, liver transplantation, and viral hepatitis.
Dr. Antonio Bertoletti is an expert in the field of viral hepatitis, with a specific interest in the immunopathogenesis of HBV infection. He began working in viral hepatitis as a medical student at the University of Parma (Italy). He continued his research work at the Scripps Research Institute (La Jolla) characterizing for the first time the Hepatitis B virus (HBV) specific cytotoxic T cell response in man. He returned to the University of Parma, where he worked in the Department of Infectious Diseases as a Clinical Scientist and then worked at the University College of London (UK) (1997-2006) before moving to Singapore where he is now Professor at the Emerging Viral Disease Program at Duke-NUS Medical School. His current research is focus on the development of new immunological based therapies (TCR-redirected T cells, HLA-peptide specific antibodies) for the treatment of HBV and HBV-related HCC.
Dr. Kyong-Mi Chang is an Associate Professor of Medicine in the Division of Gastroenterology at the University of Pennsylvania Perelman School of Medicine, with administrative leadership role as the Associate Chief of Staff and Associate Dean for Research at the Philadelphia Corporal Michael J. Crescenz VA Medical Center (CMC VAMC). Dr. Chang received her MD and Internal Medicine residency training from the Medical College of Pennsylvania, followed by clinical GI fellowship training at the University of California in San Diego, also receiving her postdoctoral research training at the Scripps Research Institute studying CTL escape in HCV persistence. She has been a faculty member in GI Division at the University of Pennsylvania School of Medicine and the CMC VAMC since 1999 with active clinical and research activities. Her translational research focuses on immune pathogenesis in human hepatitis C and B virus infection with and without HIV coinfection—including various immune regulatory mechanisms such as FoxP3+ Tregs, IL-10+ Tr1 cells, gdT-cells, PD-1 and CTLA-4. Dr. Chang is also participating in the Million Veteran Program—a multi-center VA genomic study. She is a Fellow of the American Association for Study of Liver Disease (FAASLD) and a member of the American Society for Clinical Investigation (ASCI).